288 related articles for article (PubMed ID: 35321955)
1. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk.
Han E; Lee YH; Kim YD; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Nam HS; Heo JH; Kim SU
Am J Gastroenterol; 2020 Apr; 115(4):584-595. PubMed ID: 32141917
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease.
Kim Y; Han E; Lee JS; Lee HW; Kim BK; Kim MK; Kim HS; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Lee YH; Kim SU
Gut Liver; 2022 Mar; 16(2):290-299. PubMed ID: 34238770
[TBL] [Abstract][Full Text] [Related]
5. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
6. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
7. Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease.
Chun HS; Lee M; Lee HA; Oh SY; Baek HJ; Moon JW; Kim YJ; Lee J; Kim H; Kim HY; Yoo K; Kim TH; Kim SU
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):358-369.e12. PubMed ID: 34998993
[TBL] [Abstract][Full Text] [Related]
8. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
9. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
10. Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk.
Huang YC; Huang JC; Chien HH; Lin CI; Chuang YS; Cheng HY; Lin WT; Lin YY; Chuang HY; Ho CK; Wang CL; Dai CY
Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2479-2487. PubMed ID: 37788955
[TBL] [Abstract][Full Text] [Related]
11. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
12. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
Park JH; Koo BK; Kim W; Kim WH;
Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
[TBL] [Abstract][Full Text] [Related]
13. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
14. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
Pisetta C; Chillè C; Pelizzari G; Pigozzi MG; Salvetti M; Paini A; Muiesan ML; De Ciuceis C; Ricci C; Rizzoni D
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):321-330. PubMed ID: 32436128
[TBL] [Abstract][Full Text] [Related]
16. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
17. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
18. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
Nguyen VH; Le MH; Cheung RC; Nguyen MH
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
[TBL] [Abstract][Full Text] [Related]
19. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
20. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
